FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078904498> ?p ?o ?g. }

• W2078904498 endingPage "484" @default.
• W2078904498 startingPage "478" @default.
• W2078904498 abstract "Bivalirudin, a direct thrombin inhibitor, is as effective as unfractionated heparin (UFH), with decreased bleeding in patients with acute coronary syndromes who undergo percutaneous coronary intervention (PCI). The aim of this study was to evaluate the effectiveness of bivalirudin versus UFH in selected PCI patients at high bleeding risk. Four hundred one consecutive patients who underwent PCI fulfilling ≥1 enrollment criterion (age >75 years, chronic renal failure, and diabetes mellitus) were randomized to bivalirudin (bolus 0.75 mg/kg followed by infusion during the procedure; n = 198) or UFH (75 IU/kg; n = 203). In the overall population, 39% were aged >75 years, 22% had renal failure, 63% had diabetes, and 29% had acute coronary syndromes. The primary efficacy end point was the 30-day incidence of major adverse cardiac events (cardiac death, myocardial infarction, stent thrombosis, or target vessel revascularization). The primary safety end point was the occurrence of any bleeding or entry-site complications after PCI. All patients were preloaded with clopidogrel 600 mg. Glycoprotein IIb/IIIa inhibitors were used at the operators' discretion. Thirty-day major adverse cardiac event rates were 11.1% in the bivalirudin group and 8.9% in the UFH group (p = 0.56); the primary efficacy end point was reached mainly because of periprocedural myocardial infarction; 1 patient in the bivalirudin group had stent thrombosis. Occurrence of the primary safety end point was 1.5% in the bivalirudin group and 9.9% in the UFH group (p = 0.0001); this benefit was essentially driven by the prevention of entry-site hematomas >10 cm (0.5% vs 6.9%, p = 0.002). In conclusion, Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty–Bivalirudin vs Heparin (ARMYDA-7 BIVALVE) indicates that bivalirudin, compared with UFH, causes significantly lower bleeding and has a similar incidence of major adverse cardiac events in patients with older age, diabetes mellitus, or chronic renal failure who undergo PCI. Bivalirudin, a direct thrombin inhibitor, is as effective as unfractionated heparin (UFH), with decreased bleeding in patients with acute coronary syndromes who undergo percutaneous coronary intervention (PCI). The aim of this study was to evaluate the effectiveness of bivalirudin versus UFH in selected PCI patients at high bleeding risk. Four hundred one consecutive patients who underwent PCI fulfilling ≥1 enrollment criterion (age >75 years, chronic renal failure, and diabetes mellitus) were randomized to bivalirudin (bolus 0.75 mg/kg followed by infusion during the procedure; n = 198) or UFH (75 IU/kg; n = 203). In the overall population, 39% were aged >75 years, 22% had renal failure, 63% had diabetes, and 29% had acute coronary syndromes. The primary efficacy end point was the 30-day incidence of major adverse cardiac events (cardiac death, myocardial infarction, stent thrombosis, or target vessel revascularization). The primary safety end point was the occurrence of any bleeding or entry-site complications after PCI. All patients were preloaded with clopidogrel 600 mg. Glycoprotein IIb/IIIa inhibitors were used at the operators' discretion. Thirty-day major adverse cardiac event rates were 11.1% in the bivalirudin group and 8.9% in the UFH group (p = 0.56); the primary efficacy end point was reached mainly because of periprocedural myocardial infarction; 1 patient in the bivalirudin group had stent thrombosis. Occurrence of the primary safety end point was 1.5% in the bivalirudin group and 9.9% in the UFH group (p = 0.0001); this benefit was essentially driven by the prevention of entry-site hematomas >10 cm (0.5% vs 6.9%, p = 0.002). In conclusion, Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty–Bivalirudin vs Heparin (ARMYDA-7 BIVALVE) indicates that bivalirudin, compared with UFH, causes significantly lower bleeding and has a similar incidence of major adverse cardiac events in patients with older age, diabetes mellitus, or chronic renal failure who undergo PCI." @default.
• W2078904498 created "2016-06-24" @default.
• W2078904498 creator A5005575572 @default.
• W2078904498 creator A5007714575 @default.
• W2078904498 creator A5017327209 @default.
• W2078904498 creator A5033373672 @default.
• W2078904498 creator A5051416813 @default.
• W2078904498 creator A5051460073 @default.
• W2078904498 creator A5054919035 @default.
• W2078904498 creator A5074973905 @default.
• W2078904498 creator A5089371447 @default.
• W2078904498 date "2012-08-01" @default.
• W2078904498 modified "2023-10-16" @default.
• W2078904498 title "Comparison of Safety and Efficacy of Bivalirudin Versus Unfractionated Heparin in High-Risk Patients Undergoing Percutaneous Coronary Intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty–Bivalirudin vs Heparin Study)" @default.
• W2078904498 cites W1968369112 @default.
• W2078904498 cites W1974718993 @default.
• W2078904498 cites W1984439290 @default.
• W2078904498 cites W2004110783 @default.
• W2078904498 cites W2016844884 @default.
• W2078904498 cites W2019029736 @default.
• W2078904498 cites W2030271409 @default.
• W2078904498 cites W2041936661 @default.
• W2078904498 cites W2049120615 @default.
• W2078904498 cites W2053515378 @default.
• W2078904498 cites W2056686398 @default.
• W2078904498 cites W2085869089 @default.
• W2078904498 cites W2102296549 @default.
• W2078904498 cites W2121251309 @default.
• W2078904498 cites W2144855389 @default.
• W2078904498 cites W2150086052 @default.
• W2078904498 cites W2156927593 @default.
• W2078904498 cites W2164828136 @default.
• W2078904498 cites W35937193 @default.
• W2078904498 cites W4241883936 @default.
• W2078904498 cites W2033177071 @default.
• W2078904498 doi "https://doi.org/10.1016/j.amjcard.2012.04.017" @default.
• W2078904498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22583760" @default.
• W2078904498 hasPublicationYear "2012" @default.
• W2078904498 type Work @default.
• W2078904498 sameAs 2078904498 @default.
• W2078904498 citedByCount "52" @default.
• W2078904498 countsByYear W20789044982012 @default.
• W2078904498 countsByYear W20789044982013 @default.
• W2078904498 countsByYear W20789044982014 @default.
• W2078904498 countsByYear W20789044982015 @default.
• W2078904498 countsByYear W20789044982016 @default.
• W2078904498 countsByYear W20789044982017 @default.
• W2078904498 countsByYear W20789044982018 @default.
• W2078904498 countsByYear W20789044982019 @default.
• W2078904498 countsByYear W20789044982020 @default.
• W2078904498 countsByYear W20789044982021 @default.
• W2078904498 countsByYear W20789044982022 @default.
• W2078904498 crossrefType "journal-article" @default.
• W2078904498 hasAuthorship W2078904498A5005575572 @default.
• W2078904498 hasAuthorship W2078904498A5007714575 @default.
• W2078904498 hasAuthorship W2078904498A5017327209 @default.
• W2078904498 hasAuthorship W2078904498A5033373672 @default.
• W2078904498 hasAuthorship W2078904498A5051416813 @default.
• W2078904498 hasAuthorship W2078904498A5051460073 @default.
• W2078904498 hasAuthorship W2078904498A5054919035 @default.
• W2078904498 hasAuthorship W2078904498A5074973905 @default.
• W2078904498 hasAuthorship W2078904498A5089371447 @default.
• W2078904498 hasConcept C126322002 @default.
• W2078904498 hasConcept C164705383 @default.
• W2078904498 hasConcept C168563851 @default.
• W2078904498 hasConcept C203092338 @default.
• W2078904498 hasConcept C2776301958 @default.
• W2078904498 hasConcept C2776710957 @default.
• W2078904498 hasConcept C2777557582 @default.
• W2078904498 hasConcept C2777565915 @default.
• W2078904498 hasConcept C2777849778 @default.
• W2078904498 hasConcept C2778810321 @default.
• W2078904498 hasConcept C2779161974 @default.
• W2078904498 hasConcept C2780400711 @default.
• W2078904498 hasConcept C2908647359 @default.
• W2078904498 hasConcept C35294091 @default.
• W2078904498 hasConcept C45393284 @default.
• W2078904498 hasConcept C500558357 @default.
• W2078904498 hasConcept C71924100 @default.
• W2078904498 hasConcept C99454951 @default.
• W2078904498 hasConceptScore W2078904498C126322002 @default.
• W2078904498 hasConceptScore W2078904498C164705383 @default.
• W2078904498 hasConceptScore W2078904498C168563851 @default.
• W2078904498 hasConceptScore W2078904498C203092338 @default.
• W2078904498 hasConceptScore W2078904498C2776301958 @default.
• W2078904498 hasConceptScore W2078904498C2776710957 @default.
• W2078904498 hasConceptScore W2078904498C2777557582 @default.
• W2078904498 hasConceptScore W2078904498C2777565915 @default.
• W2078904498 hasConceptScore W2078904498C2777849778 @default.
• W2078904498 hasConceptScore W2078904498C2778810321 @default.
• W2078904498 hasConceptScore W2078904498C2779161974 @default.
• W2078904498 hasConceptScore W2078904498C2780400711 @default.
• W2078904498 hasConceptScore W2078904498C2908647359 @default.
• W2078904498 hasConceptScore W2078904498C35294091 @default.
• W2078904498 hasConceptScore W2078904498C45393284 @default.
• W2078904498 hasConceptScore W2078904498C500558357 @default.
• W2078904498 hasConceptScore W2078904498C71924100 @default.
• W2078904498 hasConceptScore W2078904498C99454951 @default.

• next